Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SNOA vs BMRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SNOA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–2 Matrix Metrics)
SNOA Overall Winner
6-Pillar Tally: SNOA 5 – 0 BMRA (1 Tie)
Matrix Metrics: SNOA 7 – 2 BMRA
As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNOA carries a Unified Composite Score of 51.6/100 (HOLD) at $0.84 (46.1x Forward P/E, -3.3% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).
- Technical & Structure Timing Caution: SNOA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SNOA vs BMRA
SNOA
Head-to-Head Winner
Sonoma Pharmaceuticals, Inc. Common Stock
$0.84
-22.68% 1D
Market Cap
$5.6M
TTM Revenue
$23M
Forward P/E
46.1x
Beta / 30D Vol
1.39β · 78% Vol
Unified Composite Score
51.6
HOLD
Tech 49.0
Fund 52.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
BMRA
Biomerica Inc
$1.33
-2.32% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SNOA 5 – 0 BMRA)
1. Valuation Multiples
SNOA
Forward P/E
46.1x
N/M
Trailing P/E
46.1x
N/M
PEG Ratio
1.08x
N/M
EV / Revenue
0.2x
1.1x
2. Growth & Scale
SNOA
Revenue Growth (YoY)
+28.0%
-8.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$23M
$4.3M
Market Cap
$5.6M
$6.0M
3. Profitability & Quality
SNOA
Gross Margin
39.2%
0.9%
Operating Margin
-3.3%
-125.2%
Net Profit Margin
-7.6%
-115.5%
Return on Equity (ROE)
-34.5%
-113.8%
4. Balance Sheet & Cash Flow
SNOA
Cash Generation (TTM)
-$4.1M
-$3.2M
Cash Flow Margin
-17.6%
-73.5%
Net Cash / Leverage
$1.6M Net Cash
$1.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
SNOA
OpEx & R&D Intensity
42.5% of Rev ($10.0M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SNOA (7) vs BMRA (2)| Institutional Metric | SNOA | BMRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $5.6M | $6.0M | Tie | |
| Trailing P/E Ratio | 46.1x | N/M | SNOA | |
| Forward P/E Ratio | 46.1x | N/M | SNOA | |
| Revenue Growth (YoY) | +28.0% | -8.3% | SNOA | |
| Operating Margin (TTM) | -3.3% | -125.2% | SNOA | |
| Net Profit Margin | -7.6% | -115.5% | SNOA | |
| Return on Equity (ROE) | -34.5% | -113.8% | SNOA | |
| 52-Week Range Position | 1% ($1–$4) | 4% ($1–$3) | BMRA | |
| Beta / 30D Volatility | 1.39β · 78% Vol | 0.67β · 62% Vol | BMRA | |
| Unified Institutional Score | 51.6 / 100 (HOLD) | 44.5 / 100 (HOLD) | SNOA | |
| Trailing 12M Revenue (USD) | $23M | $4.3M | Scale | |
| Gross Profit Margin (TTM) | 39.2% | 0.9% | Quality | |
| PEG Ratio & EV / Revenue | 1.08x PEG · 0.2x EV/Rev | N/M PEG · 1.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$4.1M ($1.6M Net Cash) | -$3.2M ($1.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SNOA +3.44 pp
3M Horizon
BMRA +18.2 pp
6M Horizon
SNOA +22.79 pp
1Y Horizon
BMRA +29.33 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SNOA Revenue | BMRA Revenue | SNOA Op. Margin | BMRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $20M | $10M | -59.3% | -46.4% | BMRA |
| FY2020 | $20M | $10M | -41.2% | -41.0% | BMRA |
| FY2021 | $20M | $10M | -18.5% | -104.2% | SNOA |
| FY2022 | $10M | $20M | -46.6% | -24.0% | BMRA |
| FY2023 | $10M | $10M | -34.4% | -135.3% | SNOA |
| FY2024 | $10M | $10M | -36.9% | -117.6% | SNOA |
| FY2025 | $10M | $10M | -26.0% | -96.7% | SNOA |
| FY2026 | $20M | $0M | -12.6% | -119.5% | SNOA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SNOA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact SNOA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SNOA Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
42.5% of Rev ($10.0M)
90D Engineering Disclosures
0 Published
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SNOA vs BMRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNOA carries a Unified Composite Score of 51.6/100 (HOLD) at $0.84 (46.1x Forward P/E, -3.3% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Technical & Structure Timing Caution: SNOA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SNOA leads the Growth & Scale pillar: SNOA posts +28.0% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (39.2% gross margin, -3.3% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SNOA cumulative revenue shifted +0.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, SNOA deploys 42.5% of Rev ($10.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.
SNOA screens cheaper on headline valuation multiples. SNOA trades at 46.1x Forward P/E, 46.1x Trailing P/E, 1.08x PEG, and 0.2x EV/Revenue (-17.6% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNOA (-34.5% ROE) versus BMRA (-113.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SNOA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.39β · 78% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMRA vs SNOA · Reverse Pair
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal